© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 ...

Just before Christmas, Donald Trump announced that Sriram Krishnan, a first-generation Indian American, would serve as a senior White House policy advisor for AI. Krishnan is set to work closely ...

Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market cap in early trading on Tuesday after Pfizer (NYSE:PFE) decided to end a collaboration with the company for its gene therapy ...

Strong performance in oncology and specialty products is fueling new growth at Pfizer. The stock's 6.3% dividend is well-funded, and management has just increased it. The bar is low for ...